Every system generates the consultants it deserves. The pharmaceutical rebate system — opaque, bilateral, and structured to reward information asymmetry — has generated a cottage industry of rebate aggregators and PBM consultants who promise employers access to better rebate economics than their incumbent PBM is delivering. The pitch is compelling: your PBM is retaining a portion of the manufacturer rebates it negotiates on your behalf, and we can recapture that spread. The model is real. Whether it constitutes meaningful reform or merely a rearrangement of extraction is a harder question.
The Aggregator Value Proposition
Rebate aggregators — firms like Zinc Health Services, Emisar Pharma Services, and others — operate by pooling the rebate negotiating volume of multiple employer clients and using that scale to negotiate directly with manufacturers, bypassing the PBM’s retained spread. The economic logic parallels the GPO model in hospital supply chain: aggregated volume commands better pricing than fragmented volume, and the aggregator captures some of that improvement as its own margin while passing the remainder to clients. For employers who have historically had poor visibility into what their PBM was receiving and retaining in rebates, the aggregator offers both transparency and a better economic deal.
The actual improvement in rebate economics varies substantially by employer size, drug mix, and the baseline quality of the existing PBM contract. Large employers — those with more than five thousand covered lives using specialty drugs — tend to see the most material improvements, because their drug spend generates enough rebate volume to command meaningful aggregator attention and because the spreads their PBMs retain are large enough in absolute terms to justify the switching friction. Smaller employers often find that the aggregator’s fee offsets much of the improvement in rebate economics, leaving net savings modest. The business model is, in this sense, sized for the Fortune 500.
The New Intermediary Problem
The emergence of rebate aggregators also illustrates a recurring dynamic in healthcare market reform: responses to intermediary opacity tend to generate new intermediaries rather than eliminate the underlying opacity. An employer that moves from a PBM retaining twenty percent of manufacturer rebates to a rebate aggregator retaining eight percent has improved its economics without altering the fundamental structure of a system in which multiple intermediaries extract value from the drug distribution supply chain. The reduction in extraction is real. The elimination of extraction is not what is on offer.
The Consolidated Appropriations Act of 2021 imposed new transparency requirements on PBMs serving ERISA plans, including disclosure obligations for direct and indirect remuneration — the catch-all category that includes rebates, administrative fees, and other forms of manufacturer compensation. These requirements have given employers better information about what their PBMs are receiving, which has in some cases enabled more effective direct negotiation with their existing PBM rather than migration to an aggregator. The transparency mandates, in this reading, reduce the information advantage that made aggregators necessary in the first place. Whether they reduce it enough to displace the aggregator business model or merely change its terms is still being worked out in the market.
The Structural Question
The deeper structural question that rebate aggregators leave unaddressed is whether the rebate system itself — even with full transparency and optimal pass-through rates — produces optimal drug pricing for employers and patients. A system in which manufacturer discounts are determined by formulary placement dynamics, PBM volume, and competitive therapeutic category structure has no particular reason to produce prices that reflect drug value, patient need, or rational resource allocation. Rebate aggregators help employers extract more value from a system that has already determined prices through a different logic. They are optimization tools for an optimization problem that may itself be suboptimal.
The employers that have gone furthest in addressing this structural critique — moving to reference-based pricing, direct purchasing through Cost Plus Drugs for certain generic and specialty drugs, or carving out pharmacy benefits entirely to manage them through specialized PBMs with explicit pass-through contracts — have moved beyond the rebate system rather than optimizing within it. That is a more disruptive posture that carries its own complications, but it represents a different theory of change: that the rebate architecture is not reformable from within and must be partially circumvented. The tension between these two theories — reform within the system versus exit from it — is likely to define employer pharmacy strategy for the next decade.
